Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

SOX17 expression and its downregulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma.

Hopman ANH, Moshi JM, Hoogduin KJ, Ummelen M, Henfling MER, van Engeland M, Wouters KAD, Stoop H, Looijenga LHJ, Ramaekers FCS.

Histopathology. 2019 Aug 23. doi: 10.1111/his.13980. [Epub ahead of print]

PMID:
31444787
2.

Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review.

Lommen K, Vaes N, Aarts MJ, van Roermund JG, Schouten LJ, Oosterwijk E, Melotte V, Tjan-Heijnen VC, van Engeland M, Smits KM.

Eur Urol Oncol. 2019 Aug 9. pii: S2588-9311(19)30114-2. doi: 10.1016/j.euo.2019.07.011. [Epub ahead of print] Review.

3.

MEXPRESS update 2019.

Koch A, Jeschke J, Van Criekinge W, van Engeland M, De Meyer T.

Nucleic Acids Res. 2019 Jul 2;47(W1):W561-W565. doi: 10.1093/nar/gkz445.

4.

Molecular profiling of longitudinally observed small colorectal polyps: A cohort study.

van Lanschot MCJ, Carvalho B, Rausch C, Snaebjornsson P, van Engeland M, Kuipers EJ, Stoker J, Tutein Nolthenius CJ, Dekker E, Meijer GA.

EBioMedicine. 2019 Jan;39:292-300. doi: 10.1016/j.ebiom.2018.12.009. Epub 2018 Dec 13.

5.

Gene Promoter Methylation in Endometrial Carcinogenesis.

Cornel KMC, Wouters K, Van de Vijver KK, van der Wurff AAM, van Engeland M, Kruitwagen RFPM, Pijnenborg JMA.

Pathol Oncol Res. 2019 Apr;25(2):659-667. doi: 10.1007/s12253-018-0489-2. Epub 2018 Nov 14.

6.

A combined literature and in silico analysis enlightens the role of the NDRG family in the gut.

Vaes N, Schonkeren SL, Brosens E, Koch A, McCann CJ, Thapar N, Hofstra RMW, van Engeland M, Melotte V.

Biochim Biophys Acta Gen Subj. 2018 Oct;1862(10):2140-2151. doi: 10.1016/j.bbagen.2018.07.004. Epub 2018 Jul 7. Review.

PMID:
30033230
7.

Epigenetics in renal cell cancer: mechanisms and clinical applications.

Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC, van Engeland M.

Nat Rev Urol. 2018 Jul;15(7):430-451. doi: 10.1038/s41585-018-0023-z. Review.

PMID:
29867106
8.

Author Correction: Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, de Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):467. doi: 10.1038/s41571-018-0028-9.

PMID:
29713045
9.

Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Van Neste L, Van Criekinge W, De Meyer T, van Engeland M.

Nat Rev Clin Oncol. 2018 Jul;15(7):459-466. doi: 10.1038/s41571-018-0004-4. Review. Erratum in: Nat Rev Clin Oncol. 2018 Apr 30;:.

PMID:
29666440
10.

Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.

Draht MXG, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V, Smits KM.

Clin Epigenetics. 2018 Mar 14;10:35. doi: 10.1186/s13148-018-0461-8. eCollection 2018.

11.

Lifestyle, Diet, and Colorectal Cancer Risk According to (Epi)genetic Instability: Current Evidence and Future Directions of Molecular Pathological Epidemiology.

Hughes LAE, Simons CCJM, van den Brandt PA, van Engeland M, Weijenberg MP.

Curr Colorectal Cancer Rep. 2017;13(6):455-469. doi: 10.1007/s11888-017-0395-0. Epub 2017 Dec 2. Review.

12.

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.

Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA.

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.

13.

Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.

Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, Melotte V, van Engeland M, Tjan-Heijnen VC.

Epigenomics. 2017 Sep;9(9):1243-1257. doi: 10.2217/epi-2017-0040. Epub 2017 Aug 14. Review.

14.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11. doi: 10.1016/j.cgh.2017.07.011. Epub 2017 Jul 18.

15.

Details matter: the role of genomic location and assay standardization in DNA methylation analyses.

Lind GE, van Engeland M.

Epigenomics. 2017 Jul;9(7):933-935. doi: 10.2217/epi-2017-0053. Epub 2017 Jun 15. No abstract available.

16.

NDRG4, an early detection marker for colorectal cancer, is specifically expressed in enteric neurons.

Vaes N, Lentjes MHFM, Gijbels MJ, Rademakers G, Daenen KL, Boesmans W, Wouters KAD, Geuzens A, Qu X, Steinbusch HPJ, Rutten BPF, Baldwin SH, Sharkey KA, Hofstra RMW, van Engeland M, Vanden Berghe P, Melotte V.

Neurogastroenterol Motil. 2017 Sep;29(9). doi: 10.1111/nmo.13095. Epub 2017 May 19.

PMID:
28524415
17.

Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.

van Lanschot MC, Carvalho B, Coupé VM, van Engeland M, Dekker E, Meijer GA.

BMC Cancer. 2017 Feb 7;17(1):116. doi: 10.1186/s12885-017-3078-y.

18.

Assessing opportunities for coordinated R&D in early cancer detection and management in Europe.

Ussi AE, Rebolj M, Thorat MA, Bietrix F, Fauvel AC, Hajdúch M, Hill C, Walker I, van Engeland M, Cuzick J, Meijer G.

Int J Cancer. 2017 Apr 1;140(7):1700-1701. doi: 10.1002/ijc.30564. Epub 2016 Dec 27. No abstract available.

19.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

20.

Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.

Deckers IA, van Engeland M, van den Brandt PA, Van Neste L, Soetekouw PM, Aarts MJ, Baldewijns MM, Keszei AP, Schouten LJ.

Int J Epidemiol. 2017 Apr 1;46(2):622-631. doi: 10.1093/ije/dyw266.

PMID:
27789672
21.

Energy restriction at young age, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk in the Netherlands Cohort Study.

Simons CC, Schouten LJ, Godschalk RW, van Engeland M, van den Brandt PA, van Schooten FJ, Weijenberg MP.

Int J Cancer. 2017 Jan 15;140(2):272-284. doi: 10.1002/ijc.30439. Epub 2016 Oct 18.

22.

Potential role of gene-environment interactions in ion transport mechanisms in the etiology of renal cell cancer.

Deckers IA, van den Brandt PA, van Engeland M, van Schooten FJ, Godschalk RW, Keszei AP, Hogervorst JG, Schouten LJ.

Sci Rep. 2016 Sep 30;6:34262. doi: 10.1038/srep34262.

23.

Alcohol and Dietary Folate Intake and Promoter CpG Island Methylation in Clear-Cell Renal Cell Cancer.

Schouten LJ, Deckers IA, van den Brandt PA, Baldewijns MM, van Engeland M.

Nutr Cancer. 2016 Oct;68(7):1097-107. doi: 10.1080/01635581.2016.1187283. Epub 2016 Jun 24.

PMID:
27340879
24.

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.

Draht MX, Smits KM, Jooste V, Tournier B, Vervoort M, Ramaekers C, Chapusot C, Weijenberg MP, van Engeland M, Melotte V.

Clin Epigenetics. 2016 Apr 26;8:44. doi: 10.1186/s13148-016-0211-8. eCollection 2016.

25.

The emerging role of GATA transcription factors in development and disease.

Lentjes MH, Niessen HE, Akiyama Y, de Bruïne AP, Melotte V, van Engeland M.

Expert Rev Mol Med. 2016 Mar 8;18:e3. doi: 10.1017/erm.2016.2. Review.

26.

Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer.

Dong T, Zhang M, Dong Y, Herman JG, van Engeland M, Zhong G, Guo M.

Discov Med. 2015 Nov;20(111):261-71.

27.

Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival.

van Osch FH, Voets AM, Schouten LJ, Gottschalk RW, Simons CC, van Engeland M, Lentjes MH, van den Brandt PA, Smeets HJ, Weijenberg MP.

Carcinogenesis. 2015 Dec;36(12):1502-10. doi: 10.1093/carcin/bgv151. Epub 2015 Oct 17.

PMID:
26476438
28.

Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study.

Simons CC, Schouten LJ, Godschalk RW, van Engeland M, van den Brandt PA, van Schooten FJ, Weijenberg MP.

Sci Rep. 2015 Sep 18;5:14126. doi: 10.1038/srep14126.

29.

Body size, physical activity, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk.

Simons CC, Schouten LJ, Godschalk R, van Engeland M, van den Brandt PA, van Schooten FJ, Weijenberg MP.

Carcinogenesis. 2015 Sep;36(9):971-81. doi: 10.1093/carcin/bgv077. Epub 2015 May 29.

PMID:
26025909
30.

Prognostic Significance of Promoter Hypermethylation and Diminished Gene Expression of SYNPO2 in Melanoma.

Gao L, van den Hurk K, Nsengimana J, Laye JP, van den Oord JJ, Beck S, Gruis NA, Zoutman WH, van Engeland M, Newton-Bishop JA, Winnepenninckx VJ, van Doorn R.

J Invest Dermatol. 2015 Sep;135(9):2328-2331. doi: 10.1038/jid.2015.163. Epub 2015 Apr 28. No abstract available.

31.

Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.

Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M.

Clin Cancer Res. 2015 Aug 1;21(15):3492-500. doi: 10.1158/1078-0432.CCR-14-2049. Epub 2015 Apr 22.

32.

Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays.

de Ruijter TC, de Hoon JP, Slaats J, de Vries B, Janssen MJ, van Wezel T, Aarts MJ, van Engeland M, Tjan-Heijnen VC, Van Neste L, Veeck J.

Lab Invest. 2015 Jul;95(7):833-42. doi: 10.1038/labinvest.2015.53. Epub 2015 Apr 13.

33.

Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood.

Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, Wouters KA, Louwagie J, Schuebel KE, Herman JG, Baylin SB, van Criekinge W, Meijer GA, Ahuja N, van Engeland M.

Cancer Prev Res (Phila). 2015 Feb;8(2):157-64. doi: 10.1158/1940-6207.CAPR-14-0198. Epub 2014 Dec 23.

34.

Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.

Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, Tjan-Heijnen VC.

Biochim Biophys Acta. 2015 Jan;1855(1):1-16. doi: 10.1016/j.bbcan.2014.11.002. Epub 2014 Nov 11. Review.

PMID:
25446042
35.

Chordoma: the entity.

Yakkioui Y, van Overbeeke JJ, Santegoeds R, van Engeland M, Temel Y.

Biochim Biophys Acta. 2014 Dec;1846(2):655-69. doi: 10.1016/j.bbcan.2014.07.012. Epub 2014 Sep 3. Review.

PMID:
25193090
36.

Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.

Gao L, van den Hurk K, Moerkerk PTM, Goeman JJ, Beck S, Gruis NA, van den Oord JJ, Winnepenninckx VJ, van Engeland M, van Doorn R.

J Invest Dermatol. 2014 Dec;134(12):2957-2966. doi: 10.1038/jid.2014.270. Epub 2014 Jul 7.

37.

Polymorphisms in genes of the renin-angiotensin-aldosterone system and renal cell cancer risk: interplay with hypertension and intakes of sodium, potassium and fluid.

Deckers IA, van den Brandt PA, van Engeland M, van Schooten FJ, Godschalk RW, Keszei AP, Schouten LJ.

Int J Cancer. 2015 Mar 1;136(5):1104-16. doi: 10.1002/ijc.29060. Epub 2014 Jul 10.

38.

Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer.

Simons CC, van den Brandt PA, Stehouwer CD, van Engeland M, Weijenberg MP.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1852-62. doi: 10.1158/1055-9965.EPI-13-1285. Epub 2014 Jun 27.

39.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

40.

Epigenetics in radiotherapy: where are we heading?

Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG, Starmans MH, Boutros PC, Vooijs M, van Engeland M, Lambin P.

Radiother Oncol. 2014 May;111(2):168-77. doi: 10.1016/j.radonc.2014.05.001. Epub 2014 May 23. Review.

PMID:
24861629
41.

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N.

Ann Oncol. 2014 Dec;25(12):2314-27. doi: 10.1093/annonc/mdu149. Epub 2014 Apr 8. Review.

42.

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Draht MX, Smits KM, Tournier B, Jooste V, Chapusot C, Carvalho B, Cleven AH, Derks S, Wouters KA, Belt EJ, Stockmann HB, Bril H, Weijenberg MP, van den Brandt PA, de Bruïne AP, Herman JG, Meijer GA, Piard F, Melotte V, van Engeland M.

Mol Oncol. 2014 May;8(3):679-88. doi: 10.1016/j.molonc.2014.01.011. Epub 2014 Feb 2.

43.

Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC.

Hogervorst JG, de Bruijn-Geraets D, Schouten LJ, van Engeland M, de Kok TM, Goldbohm RA, van den Brandt PA, Weijenberg MP.

Carcinogenesis. 2014 May;35(5):1032-8. doi: 10.1093/carcin/bgu002. Epub 2014 Jan 7.

PMID:
24398672
44.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

45.

Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas.

Voorham QJ, Janssen J, Tijssen M, Snellenberg S, Mongera S, van Grieken NC, Grabsch H, Kliment M, Rembacken BJ, Mulder CJ, van Engeland M, Meijer GA, Steenbergen RD, Carvalho B.

BMC Cancer. 2013 Dec 19;13:603. doi: 10.1186/1471-2407-13-603.

46.

Long-term dietary sodium, potassium and fluid intake; exploring potential novel risk factors for renal cell cancer in the Netherlands Cohort Study on diet and cancer.

Deckers IA, van den Brandt PA, van Engeland M, Soetekouw PM, Baldewijns MM, Goldbohm RA, Schouten LJ.

Br J Cancer. 2014 Feb 4;110(3):797-801. doi: 10.1038/bjc.2013.771. Epub 2013 Dec 10.

47.

MEN1 gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids.

Swarts DR, Scarpa A, Corbo V, Van Criekinge W, van Engeland M, Gatti G, Henfling ME, Papotti M, Perren A, Ramaekers FC, Speel EJ, Volante M.

J Clin Endocrinol Metab. 2014 Feb;99(2):E374-8. doi: 10.1210/jc.2013-2782. Epub 2013 Nov 25.

48.

Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC.

Gilsing AM, Fransen F, de Kok TM, Goldbohm AR, Schouten LJ, de Bruïne AP, van Engeland M, van den Brandt PA, de Goeij AF, Weijenberg MP.

Carcinogenesis. 2013 Dec;34(12):2757-66. doi: 10.1093/carcin/bgt290. Epub 2013 Aug 27.

PMID:
23983135
49.

An exploration of pathways involved in lung carcinoid progression using gene expression profiling.

Swarts DR, Van Neste L, Henfling ME, Eijkenboom I, Eijk PP, van Velthuysen ML, Vink A, Volante M, Ylstra B, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Carcinogenesis. 2013 Dec;34(12):2726-37. doi: 10.1093/carcin/bgt271. Epub 2013 Aug 8.

50.

The CpG island methylator phenotype: what's in a name?

Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M.

Cancer Res. 2013 Oct 1;73(19):5858-68. doi: 10.1158/0008-5472.CAN-12-4306. Epub 2013 Jun 25.

Supplemental Content

Loading ...
Support Center